Literature DB >> 1475371

Ondansetron and related 5-HT3 antagonists: recent advances.

A W Oxford1, J A Bell, G J Kilpatrick, S J Ireland, M B Tyers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1475371     DOI： 10.1016/s0079-6468(08)70010-9

Source DB:  PubMed          Journal:  Prog Med Chem        ISSN： 0079-6468


× No keyword cloud information.
  6 in total

1.  Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.

Authors:  R M Eglen; C H Lee; W L Smith; L G Johnson; R Clark; R L Whiting; S S Hegde
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

Review 2.  Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 3.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

4.  Influence of ligand geometry on cholinesterase enzyme - A comparison of 1-isoindolinone based structural analog with Donepezil.

Authors:  Sunil P Upadhyay; Vikas Singh; Ram Sharma; Jianping Zhou; Pritam Thapa; David K Johnson; Andrew Keightley; Maohui Chen; William Suo; Mukut Sharma
Journal:  J Mol Struct       Date:  2021-08-31       Impact factor: 3.841

5.  The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.

Authors:  E H Wong; R Clark; E Leung; D Loury; D W Bonhaus; L Jakeman; H Parnes; R L Whiting; R M Eglen
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

6.  Base-Promoted Annulation of Amidoximes with Alkynes: Simple Access to 2,4-Disubstituted Imidazoles.

Authors:  Hina Mehmood; Muhammad Asif Iqbal; Le Lu; Ruimao Hua
Journal:  Molecules       Date:  2020-08-09       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.